Sujiang Zhang
Ruijin Hospital · Shanghai Ruijin Hospital, Shanghai Jiaotong University · Hematological Depaement, Ruijin Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sujiang Zhang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:35 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07735117 · Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AMLRuijin Hospital · not yet recruiting · Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) · principal investigator
- Ph1NCT06465550 · A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia MajorShanghai BDgene Co., Ltd. · recruiting · β-thalassemia · principal investigator
- N/ANCT06329999 · A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AMLRuijin Hospital · recruiting · Recurrent Adult Acute Myeloid Leukemia, Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia · principal investigator
- N/ANCT05776173 · Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemiaShanghai BDgene Co., Ltd. · unknown · β-thalassemia Major · principal investigator
- Ph1NCT03855371 · Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDSRuijin Hospital · unknown · P53 Mutation, Myeloid Malignancy, MDS · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 10:35 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- 60 citationsRCR 1.3
- 53 citationsRCR 1.8
- 36 citationsRCR 0.8
- A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.Clin Cancer Res · 201127 citationsRCR 0.6
- Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.Leuk Res · 20169 citationsRCR 0.3
- 6 citationsRCR 0.2
- Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy.Chin J Integr Med · 20095 citationsRCR 0.1
- [Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in 50 patients with relapsed acute myeloid leukemia].Zhongguo Shi Yan Xue Ye Xue Za Zhi · 20091 citationsRCR 0.0
- Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial.Hematol Oncol · 20241 citationsRCR 0.1
- Mutant p53 reactivation and DNA demethylation in the treatment of AML/MDS.Sci Transl Med · 2026